NORM-HF Pivotal Study
Eligible age
18+ yrs
Accepts
All genders
Locations
14 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is an international, multi-center, prospective, randomized, open-label blinded endpoint study designed to demonstrate that use of the FIRE1 NORM™ System in the management of New York Heart Association Class II/III HF patients is superior for reducing the combined endpoint of worsening HF events and cardiovascular mortality compared to standard of care treatment. Patients will be randomized in a 1:1 ratio to receive either NORM™ System and guided heart failure management (intervention group) or usual standard of care with guided heart failure management (control group).
Sponsor: Foundry Innovation & Research 1, Limited (FIRE1)
You may qualify if…
- ✓ 1. Adults 18 years of age or older.
- ✓ 2. Provide informed consent for participation in the clinical study and be willing and able to comply with the required assessments, treatment instructions, and clinical follow-up visits according to the specified schedule.
- ✓ 3. Patients meeting diagnostic criteria for HF diagnosis for greater than 90 days and are on optimally tolerated medical therapy for at least 30 days, as recommended according to current AHA/ACC/HFSA or ESC HF guidelines with any intolerance or contraindications documented, regardless of ejection fraction, as evidenced by meeting either 3a, 3b OR 3c criterion below:
- ✓ 1. NYHA functional class II with documented HF decompensation within the previous 12 months resulting in a primary HF hospitalization, HF treatment in a hospital day-care setting or unscheduled visit to a healthcare provider for administration of an intravenous diuretic to treat HF AND NT-proBNP ≥1000 pg/mL. For those patients presenting with atrial fibrillation or flutter, NT-proBNP ≥1,600 pg/mL.
- ✓ OR
- ✓ 2. NYHA functional class III with documented HF decompensation within the previous 12 months resulting in a primary HF hospitalization, HF treatment in a hospital day-care setting or unscheduled visit to a healthcare provider for administration of an intravenous diuretic to treat HF AND NT-proBNP ≥ 600 pg/mL. For patients presenting with atrial fibrillation or flutter, NT-pro BNP ≥900 pg/mL.
- ✓ OR
- ✓ 3. NYHA functional class III AND NT-proBNP ≥1000 pg/mL. For patients presenting with atrial fibrillation or flutter, NT-proBNP ≥1,600 pg/mL.
You may not qualify if…
- ✕ 1. Presence of advanced end stage HF, suggested by but not limited to:
- ✕ Persistent NYHA functional class IV HF (ACC/AHA/ESC).
- ✕ Current treatment with intravenous vasopressors or inotropes.
- ✕ Received, or are likely to receive in the next 6 months, an advanced therapy (e.g., mechanical circulatory support or cardiac transplant or previously listed for transplant).
- ✕ Receiving end of life HF care.
- ✕ 2. Severe right sided valvular disease or a right sided mechanical valve.
- ✕ 3. Patients with abdominal circumference of greater than 143 cm (56 inches) at screening.
- ✕ 4. Patients with an estimated Glomerular Filtration Rate (eGFR) \< 25 mL/min/1.73m2 or receiving ultrafiltration or chronic dialysis.
Where it's recruiting
Chula Vista · Sacramento
Jacksonville · Tampa
Baton Rouge
Boston
Kansas City
Omaha
New York
Chapel Hill
Cincinnati · Colombus · Toledo
Tulsa
Philadelphia
Columbia · Greenville
Source: ClinicalTrials.gov · NCT07574593 · last updated 2026-10-16